Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

Factors affecting hematologic recovery and infection in high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk solid tumor

소아 고형종양의 고용량 화학요법 후 자가 조혈모세포이식에서 혈액학적 회복과 감염에 영향을 주는 요인

  • Lee, Jung Hyun (Department of Pediatrics, Sungkyunkwan University School of Medicine) ;
  • Lee, Bo Lyun (Department of Pediatrics, Sungkyunkwan University School of Medicine) ;
  • Lee, Soo Hyun (Department of Pediatrics, Sungkyunkwan University School of Medicine) ;
  • Yoo, Keon Hee (Department of Pediatrics, Sungkyunkwan University School of Medicine) ;
  • Sung, Ki Woong (Department of Pediatrics, Sungkyunkwan University School of Medicine) ;
  • Jung, Hye Lim (Department of Pediatrics, Sungkyunkwan University School of Medicine) ;
  • Cho, Eun Joo (Department of Pediatrics, Sungkyunkwan University School of Medicine) ;
  • Koo, Hong Hoe (Department of Pediatrics, Sungkyunkwan University School of Medicine)
  • 이정현 (성균관대학교 의과대학 소아과학교실) ;
  • 이보련 (성균관대학교 의과대학 소아과학교실) ;
  • 이수현 (성균관대학교 의과대학 소아과학교실) ;
  • 유건희 (성균관대학교 의과대학 소아과학교실) ;
  • 성기웅 (성균관대학교 의과대학 소아과학교실) ;
  • 정혜림 (성균관대학교 의과대학 소아과학교실) ;
  • 조은주 (성균관대학교 의과대학 소아과학교실) ;
  • 구홍회 (성균관대학교 의과대학 소아과학교실)
  • Received : 2006.06.22
  • Accepted : 2006.08.23
  • Published : 2006.10.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : The purpose of this study was to evaluate factors affecting hematologic recovery and infection in high-dose chemotherapy(HDCT) and autologous stem cell transplantation(ASCT) in patients with high-risk solid tumor. Methods : From January 2004 to December 2005, 72 HDCTs and ASCTs were applied to children with high-risk solid tumor at Samsung Medical Center. Medical records of these 72 HDCTs and ASCTs were retrospectively analyzed. Results : The single most powerful predictor of neutrophil and platelet recovery was the number of transplanted $CD34^+$ cells. The duration of high fever was significantly longer in young patients, in patients treated with total body irradiation and/or thiotepa, and in patients transplanted with lower $CD34^+$ cell dose(<$2{\times}10^6/kg$). However, the difference in the duration of high fever according to the number of $CD34^+$ cells was not clinically significant. Conclusion : Findings in this study suggest that HDCT and ASCT with low $CD34^+$ cell dose is clinically feasible despite delayed hematologic recovery, especially at a dose >$1{\times}10^6/kg$ per transplantation. Therefore, it is important not to defer the appropriate time for HDCT for an additional collection of hematopoietic stem cells if the number of collected $CD34^+$ cells is >$1{\times}10^6/kg$ per transplantation.

목 적 : 본 연구는 다양한 소아 고위험 고형종양에서 이식된 조혈모세포의 수와 조혈기능의 회복속도 나아가 감염과의 상관관계에 대해 분석함으로써 자가 조혈모세포이식에서 안전한 이식을 위해 필요한 최소한의 조혈모세포의 수가 어느 정도인지를 알아보고자 하였다. 방 법 : 2004년 1월부터 2005년 12월까지 2년 동안 삼성서울병원 소아과에서 소아 고형종양을 대상으로 시행된 고용량 화학요법 후 자가 말초혈 조혈모세포이식 72례에서 이식된 조혈모세포의 수와 이식 후 혈액학적 회복속도 및 감염과의 관계를 후향적으로 분석하였다. 결 과 : 중성구 회복속도에 독립적으로 영향을 주는 유일한인자는 이식된 CD34 양성세포의 수였고 혈소판 회복속도에 독립적으로 영향을 주는 인자는 이식된 CD34 양성세포의 수와 이식 전 치료기간이었다. 미생물학적으로 확인된 감염의 빈도는 이식된 CD34 양성세포 수 등 여러 인자와 관련성이 없었다. 나이가 어릴수록, 이식 전 치료기간이 길수록, TBI 혹은 thiotepa가 포함된 고용량 화학요법, 설사가 심한 경우, 이식된 CD34 양성세포의 수가 적은 경우($2{\times}10^6/kg$ 이하) 발열기간이 유의하게 길었다. 그러나 미생물학적으로 확인된 감염의 빈도는 이러한 발열에 영향을 주는 여러 인자와 관련성이 없었다. 이식된 CD34 양성세포의 수를 보다 세분하여 중성구 및 혈소판 회복속도, 고열 지속기간 및 항생제 사용기간을 비교하였을 때 이식된 CD34 양성세포의 수가 적을수록 중성구 및 혈소판 회복속도가 늦어지고 항생제 사용기간이 길어졌으나 고열 지속 기간에는 통계적으로 유의한 차이가 없었다. 결 론 : 이식된 CD34 양성세포의 수에 따라 조혈기능의 회복속도는 분명한 차이가 있지만 미생물학적으로 확인된 감염의 빈도 혹은 임상적으로 유의한 고열 지속기간의 차이는 없었다. 따라서 고용량 화학요법 후 자가 조혈모세포이식 시 가능한 많은 수의 조혈모세포를 이식하는 것이 바람직하지만 임상적으로 충분한 조혈모세포를 채집하지 못한 경우, 1회 이식 시 최소한 $1{\times}10^6/kg$ 이상인 경우에는 임상적으로 수용할 수 있는 생착이 가능하므로 추가적인 조혈모세포 채집을 위해 고용량 화학요법의 적절한 시기를 놓치지 않는 것이 중요할 것으로 사료된다.

Keywords

References

  1. Perentesis JP, Katsanis E, Defor TE, Neglia JP, Ramsay NKC. Autologous stem cell transplantation for high-risk pediatric solid tumors. Bone Marrow transplant 1999;24: 609-15 https://doi.org/10.1038/sj.bmt.1701950
  2. Ladenstein R, Philip T, Gardner H. Autologous stem cell transplantation for solid tumors in children. Curr Opin Pediatr 1997;9:55-69 https://doi.org/10.1097/00008480-199702000-00013
  3. Michon J, Schleiermacher G. Autologous hematopoietic stem cell trasnplantation for pediatric solid tumors. Bailleire's Clinical Haematol 1999;12:247-59
  4. Hale GA. Autologous hematopoietic stem cell transplantation for pediatric solid tumors. Expert Rev Anticancer Ther 2005;5:835-46 https://doi.org/10.1586/14737140.5.5.835
  5. Alessandro B, Eugenia M, Mareva G, Sergio V, Elena V, Franca F, et al. Analysis of early infectious complications in pediatric patients undergoing bone marrow transplantation. Support Care Cancer 1999;7:253-59 https://doi.org/10.1007/s005200050257
  6. Wingard JR. Advances in the management of infections complications after bone marrow trasnplantation. Bone Marrow Transplant 1990;6:371-83
  7. Weaver CH, Hazelton B, Birch R. An analysis of engrafment kinetics as a function of the CD 34 content of peripheral blood progenitor cell collection in 692 patients after the administration of myeloablative chemotherapy. Blood 1995;86:3961-9
  8. Weaver CH, Tauer K, Zhen B. Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34＋ cell yields. J Hematother 1998;7:241-9 https://doi.org/10.1089/scd.1.1998.7.241
  9. Bentley SA, Brecher ME, Powell E, Serody JS, Wiley JM, Shea TC. Long-term engraftment failure after marrow ablation and autologous hematopoietic reconstitution : differences between peripheral blood stem cell and bone marrow recipients. Bone Marrow Trasnplant 1997;19:557-63 https://doi.org/10.1038/sj.bmt.1700717
  10. Bittencourt H, Rocha V, Chevret S. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcome after HLA-identical sibling bone marrow transplantation. Blood 2002;99:2726-33 https://doi.org/10.1182/blood.V99.8.2726
  11. Frank B, Joachim B, Stefan B, Rudolf E, Gunter H, Johann H, et al. Myeloablative megatherapy with autologous stemcell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma : a randomized controlled trial. Lancet Oncol 2005;6: 649-58 https://doi.org/10.1016/S1470-2045(05)70291-6
  12. Kletzel M, Katzenstein HM, Haut PR. Treatment of highrisk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue. Result of the Chicago Pilot II study. J Clin Oncol 2002;20:2284-92 https://doi.org/10.1200/JCO.2002.06.060
  13. Bensinger W, Appelbaum F, Rowley S. Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol 1995;13:2547-55 https://doi.org/10.1200/JCO.1995.13.10.2547
  14. Singhal S, Powles R, Treleaven J. A low CD34＋ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation form HLA-identical siblings : should CD34＋ cells/kg be considered the minimum threshold? Bone Marrow Transplant 2000;26:489-96 https://doi.org/10.1038/sj.bmt.1702542
  15. Mehta J, Powles R, Horton C, Treleaven J, Singhal S. Factors affecting engraftment and hematopoietic recovery after unpurged autografting in acute leukemia. Bone Marrow Trasnplant 1996;18:319-24
  16. Chiang KY, Worthington-White D. The clinical significance of different hematopoietic stem cell sources(primed marrow, mobilized blood, and steady state marrow) in autologous and allogeneic transplantation. Exp Hematol 2004;8:698-9
  17. Matthay KK, Harris R, Reynolds CP. Improved event free survival for autologous bone marrow transplantation vs chemotherapy in neuroblastoma : a phase III randomized Children's Cancer Study Group. J Clin Oncol 1998;17:525a
  18. Vendeguer A, Muñoz A, Cañete A, Pardo N, Donat J. Long-term results of high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma patients. Pediatr Hematol Oncol 2004;21:495-502 https://doi.org/10.1080/08880010490477284
  19. Chan KW, Petropoulos D, Choroszy M, Herzog C, Jaffe N. High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solod tumors. Bone Marrow Transplant 1997;20:1039-43 https://doi.org/10.1038/sj.bmt.1701014
  20. Sung KW, Yoo KH, Chung EH, Jung HL, Koo HH, Shin HJ. Successive double high-dose chemotherapy with peripheral blood stem cell rescue collected during a single leukapheresis round in patients with high-risk pediatric solid tumors : a pilot study in a single center. Bone Mar60row Transplant 2003;31:447-52 https://doi.org/10.1038/sj.bmt.1703869
  21. Kltzel M, Katzenstein HM, Haut PR, Yu AL, Morgan E, Reynolds M. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue : results of the Chicago pilot II study. J Clin Oncol 2002;20: 2284-92 https://doi.org/10.1200/JCO.2002.06.060
  22. Shen V, Woodbury C, Killen R, Van de Ven C, Sender L, Cairo MS. Collection and use of peripheral blood stem cells in young children with refractory solid tumors. Bone marrow Transplant 1997;19:197-204 https://doi.org/10.1038/sj.bmt.1700648
  23. Helmy A. Update in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome. Aliment Pharmacol Ther 2005;23:11-25 https://doi.org/10.1111/j.1365-2036.2006.02742.x
  24. Dulley FL, Kanfer EJ, Appelbaum FR. Veno-Occlusive disease of the liver after chemoradiotherapy and autologous bone marrow transplantation. Transplantation 1987;43:870-3 https://doi.org/10.1097/00007890-198743060-00020
  25. Kumar S, Deleve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease(sinusoidal obstruction syndrome) after hamatopoietic stem cell transplantation. Mayo Clinc Proc 2003;78:589-98 https://doi.org/10.4065/78.5.589